Eisai Introduces Lecanemab in India to Address Growing Early-Stage Alzheimer's Burden
Japanese pharmaceutical firm Eisai has launched Leqembi in India, marking the arrival of the nation's first disease-modifying therapy for early Alzheimer’s. The monoclonal antibody targets amyloid-beta plaques to slow cognitive decline in patients with mild impairment.
Key takeaways
- Eisai has launched Leqembi, India's first disease-modifying therapy for early Alzheimer's, following CDSCO marketing authorization.
- The drug utilizes monoclonal antibodies to clear amyloid-beta plaques, requiring biomarker confirmation before administration.
- India faces a significant dementia crisis, with 8.8 million elderly citizens currently affected and cases expected to double by 2036.
- Widespread adoption of the therapy faces obstacles including high costs, limited infusion infrastructure, and diagnostic testing gaps.
Therapeutic Breakthrough for Cognitive Decline
Japanese drugmaker Eisai announced the Indian market debut of Leqembi (lecanemab) on Monday, following regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO). This launch introduces the first disease-modifying therapy designed to alter the course of Alzheimer’s disease in India, specifically for patients diagnosed with mild dementia or Mild Cognitive Impairment (MCI).
Mechanism and Clinical Application
Leqembi operates as a humanized monoclonal antibody. Its primary function involves the selective targeting of aggregated amyloid-beta, facilitating the removal of existing protein plaques while inhibiting new deposits. These abnormal brain proteins typically trigger inflammation and nerve cell damage, which lead to memory loss. To qualify for this treatment, patients must first undergo diagnostic confirmation of amyloid pathology using cerebrospinal fluid or serum beta-amyloid biomarkers.
The Scale of India's Dementia Challenge
The introduction of this therapy coincides with a rising public health crisis. Data from the AIIMS-USC LASI study indicates that approximately 8.8 million Indians aged 60 and older lived with dementia in 2023, representing a 7.4 percent prevalence rate. Projections suggest these figures will nearly double by 2036, exacerbated by an aging demographic and low awareness levels.
Implementation and Barriers
Ritesh Jain, Head of Commercial Operations at Eisai India, emphasized that early intervention is vital for maximizing clinical outcomes. However, the company acknowledged significant hurdles for widespread adoption. Current challenges include gaps in early diagnostic capabilities, limited biomarker testing access, a lack of infusion infrastructure, and the absence of robust reimbursement frameworks. Eisai plans to address some of these issues through structured patient support programs to improve affordability and access.
Key Facts
- Leqembi is the first disease-modifying therapy for Alzheimer’s disease approved in India.
- Treatment is restricted to patients with early-stage symptoms and confirmed amyloid-beta pathology.
- India’s dementia population is estimated at 8.8 million and is expected to grow significantly by 2036.
- The drug functions by clearing toxic protein plaques that damage neurons and cause memory loss.
Source: The Hindu — Sci-Tech
Related stories
Fiscal Toll of Measles: New Mexico Outbreak Expenses Hit $5.4 Million
Trump Administration Exempts Open-Weight AI Models From Voluntary Safety Evaluations
India Demands Apology from Zuckerberg as Meta Faces Threat to Legal Immunity
